메뉴 건너뛰기




Volumn 16, Issue 12, 2011, Pages 1729-1740

Toxicity as a biomarker of efficacy of molecular targeted therapies: Focus on EGFR and VEGF inhibiting anticancer drugs

Author keywords

Biomarker; Efficacy; Molecular targeted therapy; Toxicity

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; HER DIMERIZATION INHIBITOR; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR;

EID: 84855186144     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0163     Document Type: Article
Times cited : (129)

References (89)
  • 1
    • 0030268577 scopus 로고    scopus 로고
    • Surrogate end points in clinical trials: Are we being misled?
    • Fleming TR, deMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996;125:605-613.
    • (1996) Ann Intern Med , vol.125 , pp. 605-613
    • Fleming, T.R.1    Demets, D.L.2
  • 2
    • 77949667760 scopus 로고    scopus 로고
    • Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents
    • Dancey JE, Dobbin KK, Groshen S et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010;16:1745-1755.
    • (2010) Clin Cancer Res , vol.16 , pp. 1745-1755
    • Dancey, J.E.1    Dobbin, K.K.2    Groshen, S.3
  • 3
    • 0034677755 scopus 로고    scopus 로고
    • Mechanism-based target identification and drug discovery in cancer research
    • Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969-1973.
    • (2000) Science , vol.287 , pp. 1969-1973
    • Gibbs, J.B.1
  • 4
    • 33749316418 scopus 로고    scopus 로고
    • The epidermal growth factor receptor pathway: A model for targeted therapy
    • Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 2006;12:5268-5272.
    • (2006) Clin Cancer Res , vol.12 , pp. 5268-5272
    • Scaltriti, M.1    Baselga, J.2
  • 5
    • 56149086186 scopus 로고    scopus 로고
    • Rash from EGFR inhibitors: Opportunities and challenges for palliation
    • Solomon BM, Jatoi A. Rash from EGFR inhibitors: Opportunities and challenges for palliation. Curr Oncol Rep 2008;10:304-308.
    • (2008) Curr Oncol Rep , vol.10 , pp. 304-308
    • Solomon, B.M.1    Jatoi, A.2
  • 6
    • 30644463008 scopus 로고    scopus 로고
    • Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies
    • Laux I, Jain A, Singh S et al. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006;94:85-92.
    • (2006) Br J Cancer , vol.94 , pp. 85-92
    • Laux, I.1    Jain, A.2    Singh, S.3
  • 7
    • 4344646459 scopus 로고    scopus 로고
    • Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
    • Pérez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
    • (2004) J Clin Oncol , vol.22 , pp. 3238-3247
    • Pérez-Soler, R.1    Chachoua, A.2    Hammond, L.A.3
  • 8
    • 44249105418 scopus 로고    scopus 로고
    • Validation of treatment induced specific adverse effect as a predictor of treatment benefit: A case study of NCIC CTG BR21
    • Ding K, Pater J, Whitehead M et al. Validation of treatment induced specific adverse effect as a predictor of treatment benefit: A case study of NCIC CTG BR21. Contemp Clin Trials 2008;29: 527-536.
    • (2008) Contemp Clin Trials , vol.29 , pp. 527-536
    • Ding, K.1    Pater, J.2    Whitehead, M.3
  • 9
    • 68949124435 scopus 로고    scopus 로고
    • Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study
    • Abstract 8007
    • O'Byrne KJ, Bondarenko I, Barrios C et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. J Clin Oncol 2009; 27(15 suppl):Abstract 8007.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 15
    • O'Byrne, K.J.1    Bondarenko, I.2    Barrios, C.3
  • 10
    • 80052254774 scopus 로고    scopus 로고
    • A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine
    • Abstract 4094
    • Manzano J, Rivera F, Galan M et al. A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine. J Clin Oncol 2010;28(15 suppl): Abstract 4094
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15
    • Manzano, J.1    Rivera, F.2    Galan, M.3
  • 11
    • 34447129570 scopus 로고    scopus 로고
    • Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
    • Wacker B, Nagrani T, Weinberg J et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13: 3913-3921.
    • (2007) Clin Cancer Res , vol.13 , pp. 3913-3921
    • Wacker, B.1    Nagrani, T.2    Weinberg, J.3
  • 12
    • 1842772526 scopus 로고    scopus 로고
    • Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
    • Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
    • (2004) J Clin Oncol , vol.22 , pp. 77-85
    • Soulieres, D.1    Senzer, N.N.2    Vokes, E.E.3
  • 13
    • 28544432807 scopus 로고    scopus 로고
    • Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    • Cohen EE, Kane MA, List MA et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11: 8418-8424.
    • (2005) Clin Cancer Res , vol.11 , pp. 8418-8424
    • Cohen, E.E.1    Kane, M.A.2    List, M.A.3
  • 14
    • 73249143536 scopus 로고    scopus 로고
    • Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
    • Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-28.
    • (2010) Lancet Oncol , vol.11 , pp. 21-28
    • Bonner, J.A.1    Harari, P.M.2    Giralt, J.3
  • 15
    • 3242720345 scopus 로고    scopus 로고
    • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    • Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
    • (2004) N Engl J Med , vol.351 , pp. 337-345
    • Cunningham, D.1    Humblet, Y.2    Siena, S.3
  • 16
    • 2142641698 scopus 로고    scopus 로고
    • Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    • Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22: 1201-1208.
    • (2004) J Clin Oncol , vol.22 , pp. 1201-1208
    • Saltz, L.B.1    Meropol, N.J.2    Loehrer Sr., P.J.3
  • 17
    • 33750615769 scopus 로고    scopus 로고
    • Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    • Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-4921.
    • (2006) J Clin Oncol , vol.24 , pp. 4914-4921
    • Lenz, H.J.1    van Cutsem, E.2    Khambata-Ford, S.3
  • 18
    • 34147103678 scopus 로고    scopus 로고
    • Openlabel phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    • Van Cutsem E, Peeters M, Siena S et al. Openlabel phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25: 1658-1664.
    • (2007) J Clin Oncol , vol.25 , pp. 1658-1664
    • van Cutsem, E.1    Peeters, M.2    Siena, S.3
  • 19
    • 79251650001 scopus 로고    scopus 로고
    • Randomized, open-label, phase III study of panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment for metastatic colorectal cancer: Efficacy by skin toxicity
    • Abstract 3528
    • Douillard J, Cassidy J, Jassem J et al. Randomized, open-label, phase III study of panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment for metastatic colorectal cancer: Efficacy by skin toxicity. J Clin Oncol 2010;28(15 suppl):Abstract 3528.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15
    • Douillard, J.1    Cassidy, J.2    Jassem, J.3
  • 20
    • 79251650001 scopus 로고    scopus 로고
    • Randomized, open-label, phase III study of panitumumab with FOLFIRI versus FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer: Efficacy by skin toxicity
    • Abstract 3529
    • Price TJ, Sobrero AF, Wilson G et al. Randomized, open-label, phase III study of panitumumab with FOLFIRI versus FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer: Efficacy by skin toxicity. J Clin Oncol 2010;28(15 suppl):Abstract 3529.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15
    • Price, T.J.1    Sobrero, A.F.2    Wilson, G.3
  • 21
    • 28944439741 scopus 로고    scopus 로고
    • Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study
    • Gordon AN, Finkler N, Edwards RP et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study. Int J Gynecol Cancer 2005;15:785-792.
    • (2005) Int J Gynecol Cancer , vol.15 , pp. 785-792
    • Gordon, A.N.1    Finkler, N.2    Edwards, R.P.3
  • 22
    • 33746678595 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer
    • Lu JF, Eppler SM, Wolf J et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006;80:136-145.
    • (2006) Clin Pharmacol Ther , vol.80 , pp. 136-145
    • Lu, J.F.1    Eppler, S.M.2    Wolf, J.3
  • 23
    • 41949140593 scopus 로고    scopus 로고
    • Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
    • Rudin CM, Liu W, Desai A et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008;26:1119-1127.
    • (2008) J Clin Oncol , vol.26 , pp. 1119-1127
    • Rudin, C.M.1    Liu, W.2    Desai, A.3
  • 24
    • 33646238486 scopus 로고    scopus 로고
    • Effects of smoking on the pharmacokinetics of erlotinib
    • Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12:2166-2171.
    • (2006) Clin Cancer Res , vol.12 , pp. 2166-2171
    • Hamilton, M.1    Wolf, J.L.2    Rusk, J.3
  • 26
    • 55249109460 scopus 로고    scopus 로고
    • Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: The EVEREST experience (preliminary data)
    • Abstract 4001
    • Tejpar S, Peeters M, Humblet Y et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: The EVEREST experience (preliminary data). J Clin Oncol 2008;26(suppl):Abstract 4001.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.
    • Tejpar, S.1    Peeters, M.2    Humblet, Y.3
  • 27
    • 0034652578 scopus 로고    scopus 로고
    • Length and loss of heterozygosity of an intron 1 polymorphic sequence of EGFR is related to cytogenetic alterations and epithelial growth factor receptor expression
    • Buerger H, Gebhardt F, Schmidt H et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of EGFR is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000;60:854-857.
    • (2000) Cancer Res , vol.60 , pp. 854-857
    • Buerger, H.1    Gebhardt, F.2    Schmidt, H.3
  • 28
    • 0040886242 scopus 로고    scopus 로고
    • Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1
    • Gebhardt F, Zänker KS, Brandt B et al. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999;274:13176-13180.
    • (1999) J Biol Chem , vol.274 , pp. 13176-13180
    • Gebhardt, F.1    Zänker, K.S.2    Brandt, B.3
  • 29
    • 10844264628 scopus 로고    scopus 로고
    • An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
    • Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64: 9139-9143.
    • (2004) Cancer Res , vol.64 , pp. 9139-9143
    • Amador, M.L.1    Oppenheimer, D.2    Perea, S.3
  • 30
    • 41149140325 scopus 로고    scopus 로고
    • Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer
    • Graziano F, Ruzzo A, Loupakis F et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008;26:1427-1434.
    • (2008) J Clin Oncol , vol.26 , pp. 1427-1434
    • Graziano, F.1    Ruzzo, A.2    Loupakis, F.3
  • 31
    • 74949098030 scopus 로고    scopus 로고
    • Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment
    • Klinghammer K, Knödler M, Schmittel A et al. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2010;16:304-310.
    • (2010) Clin Cancer Res , vol.16 , pp. 304-310
    • Klinghammer, K.1    Knödler, M.2    Schmittel, A.3
  • 32
    • 40949096067 scopus 로고    scopus 로고
    • Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
    • Liu G, Gurubhagavatula S, Zhou W et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J 2008;8:129-138.
    • (2008) Pharmacogenomics J , vol.8 , pp. 129-138
    • Liu, G.1    Gurubhagavatula, S.2    Zhou, W.3
  • 33
    • 74249092481 scopus 로고    scopus 로고
    • Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
    • Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8-18.
    • (2010) Br J Cancer , vol.102 , pp. 8-18
    • Murukesh, N.1    Dive, C.2    Jayson, G.C.3
  • 34
    • 70350002279 scopus 로고    scopus 로고
    • Adverse effects of anticancer agents that target the VEGF pathway
    • Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-477.
    • (2009) Nat Rev Clin Oncol , vol.6 , pp. 465-477
    • Chen, H.X.1    Cleck, J.N.2
  • 35
    • 33749505836 scopus 로고    scopus 로고
    • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
    • Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-1338.
    • (2006) Lancet , vol.368 , pp. 1329-1338
    • Demetri, G.D.1    van Oosterom, A.T.2    Garrett, C.R.3
  • 36
    • 33744954585 scopus 로고    scopus 로고
    • Sunitinib in patients with metastatic renal cell carcinoma
    • Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524.
    • (2006) JAMA , vol.295 , pp. 2516-2524
    • Motzer, R.J.1    Rini, B.I.2    Bukowski, R.M.3
  • 37
    • 33846260566 scopus 로고    scopus 로고
    • Sorafenib for the treatment of advanced renal cell carcinoma
    • Kane RC, Farrell AT, Saber H et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006;12:7271-7278.
    • (2006) Clin Cancer Res , vol.12 , pp. 7271-7278
    • Kane, R.C.1    Farrell, A.T.2    Saber, H.3
  • 38
    • 77955523015 scopus 로고    scopus 로고
    • Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: An updated meta-analysis
    • An MM, Zou Z, Shen H et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: An updated meta-analysis. Eur J Clin Pharmacol 2010;66:813-821.
    • (2010) Eur J Clin Pharmacol , vol.66 , pp. 813-821
    • An, M.M.1    Zou, Z.2    Shen, H.3
  • 39
    • 78649978359 scopus 로고    scopus 로고
    • Safety of bevacizumab in patients with advanced cancer: A meta-analysis of randomized controlled trials
    • Geiger-Gritsch S, Stollenwerk B, Miksad R et al. Safety of bevacizumab in patients with advanced cancer: A meta-analysis of randomized controlled trials. The Oncologist 2010;15:1179-1191.
    • (2010) The Oncologist , vol.15 , pp. 1179-1191
    • Geiger-Gritsch, S.1    Stollenwerk, B.2    Miksad, R.3
  • 40
    • 76349087360 scopus 로고    scopus 로고
    • Combination therapy: Intermittent sorafenib with bevacizumab yields activity and decreased toxicity
    • Lee JM, Sarosy GA, Annunziata CM et al. Combination therapy: Intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 2010;102:495-499.
    • (2010) Br J Cancer , vol.102 , pp. 495-499
    • Lee, J.M.1    Sarosy, G.A.2    Annunziata, C.M.3
  • 41
    • 63049093371 scopus 로고    scopus 로고
    • Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma
    • Feldman DR, Baum MS, Ginsberg MS et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432-1439.
    • (2009) J Clin Oncol , vol.27 , pp. 1432-1439
    • Feldman, D.R.1    Baum, M.S.2    Ginsberg, M.S.3
  • 42
    • 70349673595 scopus 로고    scopus 로고
    • Aphase I study of sunitinib plus bevacizumab in advanced solid tumors
    • Rini BI, Garcia JA, Cooney MM et al. Aphase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009;15:6277-6283.
    • (2009) Clin Cancer Res , vol.15 , pp. 6277-6283
    • Rini, B.I.1    Garcia, J.A.2    Cooney, M.M.3
  • 43
    • 70349696526 scopus 로고    scopus 로고
    • Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment
    • Maitland ML, Kasza KE, Karrison T et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009;15:6250-6257.
    • (2009) Clin Cancer Res , vol.15 , pp. 6250-6257
    • Maitland, M.L.1    Kasza, K.E.2    Karrison, T.3
  • 44
    • 66149147757 scopus 로고    scopus 로고
    • Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer
    • Allegra CJ, Yothers G, O'Connell MJ et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009;27:3385-3390.
    • (2009) J Clin Oncol , vol.27 , pp. 3385-3390
    • Allegra, C.J.1    Yothers, G.2    O'Connell, M.J.3
  • 45
    • 33645449812 scopus 로고    scopus 로고
    • Mechanisms of hypertension associated with BAY 43-9006
    • Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24:1363-1369.
    • (2006) J Clin Oncol , vol.24 , pp. 1363-1369
    • Veronese, M.L.1    Mosenkis, A.2    Flaherty, K.T.3
  • 46
    • 51849167221 scopus 로고    scopus 로고
    • Mechanism of bevacizumab-induced arterial hypertension: Relation with skin capillary rarefaction in patients treated for metastatic colorectal cancer
    • Abstract 3557
    • Morere JF, Des Guetz G, Mourad J et al. Mechanism of bevacizumab-induced arterial hypertension: Relation with skin capillary rarefaction in patients treated for metastatic colorectal cancer. J Clin Oncol 2007;25(18 suppl):Abstract 3557.
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL. 18
    • Morere, J.F.1    des Guetz, G.2    Mourad, J.3
  • 47
    • 77949400086 scopus 로고    scopus 로고
    • Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib
    • van der Veldt AA, de Boer MP, Boven E et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs 2010;21:439-446.
    • (2010) Anticancer Drugs , vol.21 , pp. 439-446
    • van der Veldt, A.A.1    de Boer, M.P.2    Boven, E.3
  • 48
    • 50349101200 scopus 로고    scopus 로고
    • Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor
    • Steeghs N, Gelderblom H, Roodt JO et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008;14:3470-3476.
    • (2008) Clin Cancer Res , vol.14 , pp. 3470-3476
    • Steeghs, N.1    Gelderblom, H.2    Roodt, J.O.3
  • 49
    • 77953354537 scopus 로고    scopus 로고
    • Reversibility of capillary density after discontinuation of bevacizumab treatment
    • Steeghs N, Rabelink TJ, op't Roodt J et al. Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol 2010; 21:1100-1105.
    • (2010) Ann Oncol , vol.21 , pp. 1100-1105
    • Steeghs, N.1    Rabelink, T.J.2    Op't roodt, J.3
  • 50
    • 77956105935 scopus 로고    scopus 로고
    • Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon
    • de Boer MP, van der Veldt AA, Lankheet NA et al. Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon. Ann Oncol 2010;21:1923-1924.
    • (2010) Ann Oncol , vol.21 , pp. 1923-1924
    • de Boer, M.P.1    van der Veldt, A.A.2    Lankheet, N.A.3
  • 51
    • 60549118166 scopus 로고    scopus 로고
    • Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
    • Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-230.
    • (2009) Ann Oncol , vol.20 , pp. 227-230
    • Scartozzi, M.1    Galizia, E.2    Chiorrini, S.3
  • 52
    • 84855186161 scopus 로고    scopus 로고
    • Hypertension and survival in unresectable metastatic colorectal cancer (mCRC) patients receiving first-line bevacizumab (BEV) and FOLFOX
    • Abstract e14066
    • Burnette BL, Grothey A. Hypertension and survival in unresectable metastatic colorectal cancer (mCRC) patients receiving first-line bevacizumab (BEV) and FOLFOX. J Clin Oncol 2010; 28(suppl):Abstract e14066.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL.
    • Burnette, B.L.1    Grothey, A.2
  • 53
    • 82455166762 scopus 로고    scopus 로고
    • Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients
    • Mar 16 [Epub ahead of print]
    • de Stefano A, Carlomagno C, Pepe S et al. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 2011 Mar 16 [Epub ahead of print].
    • (2011) Cancer Chemother Pharmacol
    • de Stefano, A.1    Carlomagno, C.2    Pepe, S.3
  • 54
    • 33645553328 scopus 로고    scopus 로고
    • Early hypertension as a potential pharmacodynamic marker for survival in pancreatic cancer patients treated with bevacizumab and gemcitabine
    • Abstract 3020
    • Friberg G, Kasza K, Vokes EE et al. Early hypertension as a potential pharmacodynamic marker for survival in pancreatic cancer patients treated with bevacizumab and gemcitabine. J Clin Oncol 2005;23(16 suppl):Abstract 3020.
    • (2005) J Clin Oncol , vol.23 , Issue.SUPPL. 16
    • Friberg, G.1    Kasza, K.2    Vokes, E.E.3
  • 55
    • 65549088617 scopus 로고    scopus 로고
    • Association of diastolic blood pressure> 90 mmHg with overall survival in patients treated with axitinib (AG-013736)
    • Abstract 3543
    • Rini BI, Schiller JH, Fruehauf JP et al. Association of diastolic blood pressure> 90 mmHg with overall survival in patients treated with axitinib (AG-013736). J Clin Oncol 2008;26(suppl): Abstract 3543.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.
    • Rini, B.I.1    Schiller, J.H.2    Fruehauf, J.P.3
  • 56
    • 60549095633 scopus 로고    scopus 로고
    • Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
    • Bono P, Elfving H, Utriainen T et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009;20:393-394.
    • (2009) Ann Oncol , vol.20 , pp. 393-394
    • Bono, P.1    Elfving, H.2    Utriainen, T.3
  • 58
    • 84855183991 scopus 로고    scopus 로고
    • Association of hypertension with overall outcome in patients taking sorafenib in advanced hepatocellular carcinoma
    • Abstract e14536
    • Kim RD, Byrne MT, Hammel J et al. Association of hypertension with overall outcome in patients taking sorafenib in advanced hepatocellular carcinoma. J Clin Oncol 2010;28(suppl):Abstract e14536.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL.
    • Kim, R.D.1    Byrne, M.T.2    Hammel, J.3
  • 59
    • 78049399444 scopus 로고    scopus 로고
    • Analysis of early hypertension and clinical outcome with bevacizumab
    • Abstract 3039
    • Hurwitz H, Douglas PS, Middleton JP et al. Analysis of early hypertension and clinical outcome with bevacizumab. J Clin Oncol 2010;28(15 suppl):Abstract 3039.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15
    • Hurwitz, H.1    Douglas, P.S.2    Middleton, J.P.3
  • 60
    • 53749093040 scopus 로고    scopus 로고
    • Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    • Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.
    • (2008) J Clin Oncol , vol.26 , pp. 4672-4678
    • Schneider, B.P.1    Wang, M.2    Radovich, M.3
  • 61
    • 77949894217 scopus 로고    scopus 로고
    • Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599
    • Dahlberg SE, Sandler AB, Brahmer JR et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28:949-954.
    • (2010) J Clin Oncol , vol.28 , pp. 949-954
    • Dahlberg, S.E.1    Sandler, A.B.2    Brahmer, J.R.3
  • 62
    • 77953628821 scopus 로고    scopus 로고
    • MO19390 (SAiL): Hypertension in patients with advanced of recurrent non-squamous non-small cell lung cancer receiving first-line bevacizumab plus chemotherapy
    • Abstract C2.4
    • Thatcher N, Tsai CM, Laskin J et al. MO19390 (SAiL): Hypertension in patients with advanced of recurrent non-squamous non-small cell lung cancer receiving first-line bevacizumab plus chemotherapy. J Thor Oncol 2009;4(suppl): Abstract C2.4.
    • (2009) J Thor Oncol , vol.4 , Issue.SUPPL.
    • Thatcher, N.1    Tsai, C.M.2    Laskin, J.3
  • 63
    • 77952318310 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206
    • Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 2010;28:2137-2143.
    • (2010) J Clin Oncol , vol.28 , pp. 2137-2143
    • Rini, B.I.1    Halabi, S.2    Rosenberg, J.E.3
  • 64
    • 34447343347 scopus 로고    scopus 로고
    • Hypertension as a predictive factor of sunitinib activity
    • Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007;18:1117.
    • (2007) Ann Oncol , vol.18 , pp. 1117
    • Rixe, O.1    Billemont, B.2    Izzedine, H.3
  • 65
    • 77958063197 scopus 로고    scopus 로고
    • Hypertension (HTN) as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib [abstract 312]
    • San Francisco, California, March 7
    • Rini BI, Cohen DP, Lu D et al. Hypertension (HTN) as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib [abstract 312]. Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, California, March 7, 2010.
    • (2010) Presented At the American Society of Clinical Oncology Genitourinary Cancers Symposium
    • Rini, B.I.1    Cohen, D.P.2    Lu, D.3
  • 66
    • 77958470973 scopus 로고    scopus 로고
    • Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24
    • Goodwin R, Ding K, Seymour L et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 2010;21:2220-2226.
    • (2010) Ann Oncol , vol.21 , pp. 2220-2226
    • Goodwin, R.1    Ding, K.2    Seymour, L.3
  • 67
    • 77649125649 scopus 로고    scopus 로고
    • Diastolic blood pressure and pharmacokinetics as predictors of axitinib efficacy in metastatic renal cell cancer
    • Abstract 5045
    • Rixe O, Dutcher J, Motzer R et al. Diastolic blood pressure and pharmacokinetics as predictors of axitinib efficacy in metastatic renal cell cancer. J Clin Oncol 2009;27(15 suppl):Abstract 5045.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 15
    • Rixe, O.1    Dutcher, J.2    Motzer, R.3
  • 68
    • 77649109910 scopus 로고    scopus 로고
    • VEGF single nucleotide polymorphisms and correlation to sunitinib-induced hypertension in metastatic renal cell carcinoma patients
    • Abstract 5005
    • Kim JJ, Vaziri SA, Elson P et al. VEGF single nucleotide polymorphisms and correlation to sunitinib-induced hypertension in metastatic renal cell carcinoma patients. J Clin Oncol 2009;27(15 suppl):Abstract 5005.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 15
    • Kim, J.J.1    Vaziri, S.A.2    Elson, P.3
  • 69
    • 79959290713 scopus 로고    scopus 로고
    • Role of VEGF and VEGFR2 single nucleotide polymorphisms in predicting treatment-induced hypertension and clinical outcome in metastatic clear cell RCC patients treated with sunitinib
    • Abstract 4629
    • Kim JJ, Vaziri SA, Elson P et al. Role of VEGF and VEGFR2 single nucleotide polymorphisms in predicting treatment-induced hypertension and clinical outcome in metastatic clear cell RCC patients treated with sunitinib. J Clin Oncol 2010;28(15 suppl):Abstract 4629.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15
    • Kim, J.J.1    Vaziri, S.A.2    Elson, P.3
  • 70
    • 70349685095 scopus 로고    scopus 로고
    • Rapid develop-ment of hypertension by sorafenib: Toxicity or target?
    • Humphreys BD, Atkins MB. Rapid develop-ment of hypertension by sorafenib: Toxicity or target? Clin Cancer Res 2009;15:5947-5949.
    • (2009) Clin Cancer Res , vol.15 , pp. 5947-5949
    • Humphreys, B.D.1    Atkins, M.B.2
  • 71
    • 33846978108 scopus 로고    scopus 로고
    • Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
    • Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81-83.
    • (2007) J Natl Cancer Inst , vol.99 , pp. 81-83
    • Rini, B.I.1    Tamaskar, I.2    Shaheen, P.3
  • 72
    • 48349122489 scopus 로고    scopus 로고
    • The clinical implications of sunitinib-induced hypothyroidism: A prospective evaluation
    • Wolter P, Stefan C, Decallonne B et al. The clinical implications of sunitinib-induced hypothyroidism: A prospective evaluation. Br J Cancer 2008;99:448-454.
    • (2008) Br J Cancer , vol.99 , pp. 448-454
    • Wolter, P.1    Stefan, C.2    Decallonne, B.3
  • 73
    • 38849093794 scopus 로고    scopus 로고
    • Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
    • Tamaskar I, Bukowski R, Elson P et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008;19:265-268.
    • (2008) Ann Oncol , vol.19 , pp. 265-268
    • Tamaskar, I.1    Bukowski, R.2    Elson, P.3
  • 74
    • 77649310826 scopus 로고    scopus 로고
    • Sunitinib induces hypothyroidism with a markedly reduced vascularity
    • Makita N, Miyakawa M, Fujita T et al. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 2010;20:323-326.
    • (2010) Thyroid , vol.20 , pp. 323-326
    • Makita, N.1    Miyakawa, M.2    Fujita, T.3
  • 75
    • 34548764576 scopus 로고    scopus 로고
    • A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
    • Mannavola D, Coco P, Vannucchi G et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92: 3531-3534.
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 3531-3534
    • Mannavola, D.1    Coco, P.2    Vannucchi, G.3
  • 76
    • 34248632840 scopus 로고    scopus 로고
    • Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
    • Wong E, Rosen LS, Mulay M et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17:351-355.
    • (2007) Thyroid , vol.17 , pp. 351-355
    • Wong, E.1    Rosen, L.S.2    Mulay, M.3
  • 77
    • 84855186163 scopus 로고    scopus 로고
    • Hypothyroidism and survival during sunitinib therapy in metastatic renal cell carcinoma (mRCC): A prospective observational analysis
    • Abstract e15013
    • Bladou F, Gravis G, Sabatier R et al. Hypothyroidism and survival during sunitinib therapy in metastatic renal cell carcinoma (mRCC): A prospective observational analysis. J Clin Oncol 2010; 28(suppl):Abstract e15013.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL.
    • Bladou, F.1    Gravis, G.2    Sabatier, R.3
  • 78
    • 79551543816 scopus 로고    scopus 로고
    • The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center study
    • Sep, Epub ahead of print
    • Baldazzi V, Tassi R, Lapini A et al. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center study. Urologic Oncol 2010 Sep 28 [Epub ahead of print].
    • (2010) Urologic Oncol , vol.28
    • Baldazzi, V.1    Tassi, R.2    Lapini, A.3
  • 79
    • 78651361788 scopus 로고    scopus 로고
    • Hypothyroidism in patients with renal cell carcinoma: Blessing or curse?
    • Schmidinger M, Vogl UM, Bojic M et al. Hypothyroidism in patients with renal cell carcinoma: Blessing or curse? Cancer 2011;117:534-544.
    • (2011) Cancer , vol.117 , pp. 534-544
    • Schmidinger, M.1    Vogl, U.M.2    Bojic, M.3
  • 80
    • 0019503711 scopus 로고
    • Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism
    • Mishkin SY, Pollack R, Yalovsky MA et al. Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism. Cancer Res 1981;41:3040-3045.
    • (1981) Cancer Res , vol.41 , pp. 3040-3045
    • Mishkin, S.Y.1    Pollack, R.2    Yalovsky, M.A.3
  • 81
    • 0033570240 scopus 로고    scopus 로고
    • Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice
    • Theodossiou C, Skrepnik N, Robert EG et al. Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice. Cancer 1999;86:1596-1601.
    • (1999) Cancer , vol.86 , pp. 1596-1601
    • Theodossiou, C.1    Skrepnik, N.2    Robert, E.G.3
  • 82
    • 33750162642 scopus 로고    scopus 로고
    • Association between development of hypothyroidism and improved survival in patients with head and neck cancer
    • Nelson M, Hercbergs A, Rybicki L et al. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132:1041-1046.
    • (2006) Arch Otolaryngol Head Neck Surg , vol.132 , pp. 1041-1046
    • Nelson, M.1    Hercbergs, A.2    Rybicki, L.3
  • 83
    • 0037235850 scopus 로고    scopus 로고
    • Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: A phase I/II study
    • Hercbergs AA, Goyal LK, Suh JH et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: A phase I/II study. Anticancer Res 2003;23:617-626.
    • (2003) Anticancer Res , vol.23 , pp. 617-626
    • Hercbergs, A.A.1    Goyal, L.K.2    Suh, J.H.3
  • 84
    • 20044370107 scopus 로고    scopus 로고
    • Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma
    • Cristofanilli M, Yamamura Y, Kau SW et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005; 103:1122-1128.
    • (2005) Cancer , vol.103 , pp. 1122-1128
    • Cristofanilli, M.1    Yamamura, Y.2    Kau, S.W.3
  • 85
    • 0021183285 scopus 로고
    • Regulation of epidermal growth factor receptor levels by thyroid hormone
    • Mukku VR. Regulation of epidermal growth factor receptor levels by thyroid hormone. J Biol Chem 1984;259:6543-6547.
    • (1984) J Biol Chem , vol.259 , pp. 6543-6547
    • Mukku, V.R.1
  • 86
    • 22144494707 scopus 로고    scopus 로고
    • Integrin αVβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis
    • Bergh JJ, Lin HY, Lansing L et al. Integrin αVβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005;146:2864-2871.
    • (2005) Endocrinology , vol.146 , pp. 2864-2871
    • Bergh, J.J.1    Lin, H.Y.2    Lansing, L.3
  • 87
    • 55549092771 scopus 로고    scopus 로고
    • Documentation of thyroid function in clinical studies with sunitinib: Why does it matter?
    • Garfield DH, Wolter P, Schöffski P et al. Documentation of thyroid function in clinical studies with sunitinib: Why does it matter? J Clin Oncol 2008;26:5131-5132.
    • (2008) J Clin Oncol , vol.26 , pp. 5131-5132
    • Garfield, D.H.1    Wolter, P.2    Schöffski, P.3
  • 88
    • 69849108427 scopus 로고    scopus 로고
    • Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges
    • Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-4034.
    • (2009) J Clin Oncol , vol.27 , pp. 4027-4034
    • Mandrekar, S.J.1    Sargent, D.J.2
  • 89
    • 84855186162 scopus 로고    scopus 로고
    • Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response
    • Abstract 3091
    • Nallari AS, Karrison T, Rosner GL et al. Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response. J Clin Oncol 2010;28(15 suppl):Abstract 3091.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15
    • Nallari, A.S.1    Karrison, T.2    Rosner, G.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.